Recursion Pharmaceuticals (RXRX) Assets Average (2021 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Assets Average came in at $1.4 billion in Q1 2026, up 2.17% YoY from $1.4 billion in Q1 2025, and down 2.09% on a QoQ basis from $1.4 billion in Q4 2025.
Recursion Pharmaceuticals (RXRX) Assets Average (2021 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 6 years of Assets Average data on file, last reported at $1.4 billion in Q1 2026.
- Quarterly Assets Average rose 2.17% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 2.17% YoY) and the FY2025 annual result came in at $1.5 billion, up 39.03% from the prior year.
- Assets Average declined to $1.4 billion in Q1 2026, from $1.4 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $1.4 billion in Q4 2025 to a low of $605.8 million in Q1 2024.
- A 5-year average of $897.8 million and a median of $672.3 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average surged 135.69% — and 2024, when it slipped 8.81%.
- Tracing RXRX's Assets Average over 5 years: stood at $656.4 million in 2022, then slipped by 2.16% to $642.3 million in 2023, then soared by 69.33% to $1.1 billion in 2024, then jumped by 32.12% to $1.4 billion in 2025, then dropped by 2.09% to $1.4 billion in 2026.
- The last three Assets Average figures came in at $1.4 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 1.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.28 Bn |
| Mar 31, 2026 | 1.41 Bn |
| Dec 31, 2025 | 1.44 Bn |
| Sep 30, 2025 | 1.35 Bn |
| Jun 30, 2025 | 1.30 Bn |
| Mar 31, 2025 | 1.38 Bn |
| Dec 31, 2024 | 1.09 Bn |
| Sep 30, 2024 | 751.18 Mn |
| Jun 30, 2024 | 666.85 Mn |
| Mar 31, 2024 | 605.77 Mn |
| Dec 31, 2023 | 642.26 Mn |
| Sep 30, 2023 | 648.76 Mn |
| Jun 30, 2023 | 647.03 Mn |
| Mar 31, 2023 | 664.33 Mn |
| Dec 31, 2022 | 656.41 Mn |
| Sep 30, 2022 | 642.02 Mn |
| Jun 30, 2022 | 703.42 Mn |
| Mar 31, 2022 | 672.33 Mn |
| Dec 31, 2021 | 634.48 Mn |
| Sep 30, 2021 | 678.60 Mn |